title: Pharmacology and laboratory testing of the oral Xa inhibitors.
abstract: New oral factor Xa inhibitors are intended to progressively substitute the oral vitamin K antagonists and parenteral indirect inhibitors of factor Xa in the prevention and treatment of venous and arterial thromboembolic episodes. This article focuses on the main clinical studies and on biological measurements of new oral factor Xa inhibitors, and addresses several safety issues. These newer agents do not require any routine laboratory monitoring of blood coagulation; however, biological tests have been developed in order to assess the plasma concentration of these drugs in several clinical settings. This article reviews these 4 oral direct factor Xa inhibitors.
authors.affiliation: Department of Biological Hematology, Cochin Hôtel-Dieu University Hospitals, 27 rue du Faubourg St-Jacques, Paris 75014, France; BIOMNIS Laboratories, 78 Avenue de Verdun, Ivry-sur-Seine 94200, France.
authors.forename: Meyer Michel
authors.initials: MM
authors.lastname: Samama
authors.affiliation: Department of Biological Hematology, Cochin Hôtel-Dieu University Hospitals, 27 rue du Faubourg St-Jacques, Paris 75014, France; BIOMNIS Laboratories, 78 Avenue de Verdun, Ivry-sur-Seine 94200, France.
authors.forename: Sadia
authors.initials: S
authors.lastname: Meddahi
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, Cochin Hôtel-Dieu University Hospitals, 27 rue du Faubourg St-Jacques, Paris 75014, France. Electronic address: marc.samama@cch.aphp.fr.
authors.forename: Charles Marc
authors.initials: CM
authors.lastname: Samama
mesh_terms: D000284:Administration, Oral; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D001780:Blood Coagulation Tests; D016903:Drug Monitoring / Q000379:methods*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D057285:Precision Medicine; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D000069552:Rivaroxaban; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D001549:Benzamides; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; C522181:apixaban; C543086:betrixaban; D000069552:Rivaroxaban; C552171:edoxaban
keywords: Apixaban; Betrixaban; Bleeding; Edoxaban; Monitoring; Rivaroxaban